Abstract:In the past, little attention had been paid to the intestine and its microbial flora as a potential source of systemic inflammation in chronic kidney disease(CKD). Systemic inflammation plays a central role in progression of CKD and its cardiovascular and various other complications. The gastrointestinal tract houses a large community of microbes that have a symbiotic relationship with the host. The normal microbial flora protects the host against pathogenic microorganisms. It also contributes to the energy metabolism, micronutrient homeostasis and nitrogen bal- ance. Recent studies have revealed significant changes in the composition and function of the microbial flora in CKD patients and animals. These changes are driven by altered intestinal bio- chemical environment caused by: I-heavy influx of urea and uric acid from body fluids into the gastrointestinal tract, II- restrictions of potassium-rich food including fruits and vegetables which as the main source of indigestible complex carbohydrates are the essential nutrients for the guts' symbiotic microbial com- munity, and III- various medications such as phosphate binders, antibiotics etc. Together the changes in intestinal milieu and the resultant microbial dysbiosis play a major role in systemic inflammation and uremic toxicity by several mechanisms : I-generation of several microbial derived uremic toxins such as indoxyl sulfate, p-cresol sulfate and trimethylamine-N-oxide etc. II-reduction of microbial derived micronutrients such a short chain fatty acids (SCFA) which are the main source of nutrients for colonocytes. This is caused by diminished substrates (indigestible complex carbohydrates) which leads to depletion of SCFA-making bacteria. In addition, III-Disruption of the intestinal epithelial barrier by ammonia and ammonium hydroxide generated from hydrolysis of urea by urease-possessing microbial species which are common complications of CKD, and bowel ischemia caused by excessive use of diuretics (in CKD patients) and aggressive ultrafiltration by hemodialysis (in ESRD patients) can impair gastrointestinal epithelial barrier. The resulting breakdown of the gut epithelial barrier (tight junction complex) leads to influx of endotoxin, microbial fragments, and other noxious luminal products in the sub-epithelial tissue and systemic circulation leading to local and systemic inflammation and oxidative stress which are the major cause of morbidity and mortality in CKD population. This review is intended to provide an overview of the effects of CKD on the gut microbiome and intestinal epithelial barrier structure and the potential interventions aimed at mitigating these abnormalities.

The impact of gut microbiota on kidney function and pathogenesis

Chronic kidney disease and gut microbiota

The gut microbiota and its relationship with chronic kidney disease

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

Recent advances of gut microbiota in chronic kidney disease patients

Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease

Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis

Chronic kidney disease and the gut microbiome

Gut microbiome and kidney disease: a bidirectional relationship

[Uremic toxins and gut micro biome]

The Impact of CKD on Uremic Toxins and Gut Microbiota

The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies

Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease

Homeostasis in the Gut Microbiota in Chronic Kidney Disease

Link between gut microbiota dysbiosis and chronic kidney disease.

Kidneys and microbiota

An Overview of Chronic Kidney Disease Pathophysiology: The Impact of Gut Dysbiosis and Oral Disease

The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease

CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity

Gut microbial metabolites SCFAs and chronic kidney disease